Piper Jaffray Companies restated their overweight rating on shares of Gemphire Therapeutics Inc (NASDAQ:GEMP) in a report published on Friday morning, MarketBeat reports. They currently have a $22.00 target price on the stock.

A number of other research firms also recently issued reports on GEMP. Jefferies Group LLC raised their target price on Gemphire Therapeutics to $32.00 and gave the stock a buy rating in a research report on Tuesday, August 1st. Zacks Investment Research raised Gemphire Therapeutics from a hold rating to a strong-buy rating and set a $22.00 target price for the company in a research report on Thursday, August 3rd. Canaccord Genuity set a $31.00 target price on Gemphire Therapeutics and gave the stock a buy rating in a research report on Wednesday, July 26th. Finally, Roth Capital began coverage on Gemphire Therapeutics in a research report on Thursday, October 19th. They issued a buy rating and a $30.00 target price for the company. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the company’s stock. Gemphire Therapeutics presently has a consensus rating of Buy and an average target price of $22.00.

Gemphire Therapeutics (NASDAQ GEMP) traded down 0.29% on Friday, hitting $10.19. The company’s stock had a trading volume of 37,693 shares. The stock’s market cap is $108.28 million. The firm has a 50 day moving average of $9.65 and a 200-day moving average of $9.65. Gemphire Therapeutics has a 12 month low of $7.20 and a 12 month high of $21.59.

Gemphire Therapeutics (NASDAQ:GEMP) last released its earnings results on Monday, August 14th. The company reported ($0.99) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.71) by ($0.28). On average, analysts expect that Gemphire Therapeutics will post ($3.00) earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: This story was originally published by Daily Political and is the sole property of of Daily Political. If you are viewing this story on another website, it was copied illegally and reposted in violation of United States & international trademark and copyright legislation. The original version of this story can be accessed at https://www.dailypolitical.com/2017/10/30/gemphire-therapeutics-inc-gemp-earns-overweight-rating-from-piper-jaffray-companies.html.

Several hedge funds and other institutional investors have recently made changes to their positions in GEMP. Renaissance Technologies LLC purchased a new position in shares of Gemphire Therapeutics in the first quarter valued at $184,000. Northpointe Capital LLC purchased a new position in shares of Gemphire Therapeutics in the second quarter valued at $3,472,000. Cambridge Investment Research Advisors Inc. grew its position in shares of Gemphire Therapeutics by 1.7% in the second quarter. Cambridge Investment Research Advisors Inc. now owns 153,064 shares of the company’s stock valued at $1,959,000 after purchasing an additional 2,500 shares in the last quarter. Vanguard Group Inc. grew its position in shares of Gemphire Therapeutics by 137.6% in the second quarter. Vanguard Group Inc. now owns 30,898 shares of the company’s stock valued at $399,000 after purchasing an additional 17,892 shares in the last quarter. Finally, GM Advisory Group Inc. purchased a new position in shares of Gemphire Therapeutics in the second quarter valued at $457,000. Institutional investors own 32.06% of the company’s stock.

About Gemphire Therapeutics

Gemphire Therapeutics Inc is a clinical-stage biopharmaceutical company. The Company is engaged in the development and commercialization of therapeutics to treat cardiovascular and metabolic diseases. It is developing its product candidate, gemcabene (CI-1027), which is a once-daily, oral therapy for patients who are unable to achieve normal levels of low-density lipoprotein cholesterol (LDL-C) or triglycerides with approved therapies, primarily statin therapy.

Analyst Recommendations for Gemphire Therapeutics (NASDAQ:GEMP)

Receive News & Ratings for Gemphire Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gemphire Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.